XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.2
SHAREHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 11:-
SHAREHOLDERS' EQUITY
 
  a.
Share capital:
 
Ordinary shares confer upon their holders voting rights, the right to receive cash dividends and the right to share in excess assets upon liquidation of the Company.
 
  b.
Stock option plans:
 
Description of plans:
 
In October 2008, the Company's Board of Directors adopted the 2008 Stock Incentive Plan (the "2008 Plan") with 1,000,000 shares or stock options available for grant and a sub-plan to enable qualified optionees certain tax benefits under the Israeli Income Tax Ordinance. Among the incentives that may be adopted are stock options, performance share awards, performance share unit awards, restricted shares, RSUs awards and other stock-based awards. During the years commencing in 2010 and through December 31, 2024, the Company's Board of Directors approved, in the aggregate, an increase of 11,047,611 shares to the number of shares available for grant under the 2008 Plan, bringing the total number of shares available for grant to 12,047,611. As of December 31, 2024, 918,125 shares were available for future grants under the 2008 Plan.
 
The options granted under the 2008 Plan to the Company’s employees generally vest over a four-year period. The options granted under the 2008 Plan to the Company’s directors generally vest ratably each quarter over a three-year period except in the case of the grant to the Company’s Chairman of the Board of Directors, in which the options vest ratably each quarter over a four-year period.
 
In February 2019, the 2008 Plan was amended to include a dividend adjustment, reducing the exercise price of outstanding share options by the cash dividend paid per share unless otherwise resolved by the Board. The amendment also allows the administering committee to apply a “net exercise” method, while withholding a portion of shares based on a specified formula.
 
Valuation assumptions:
 
The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its stock options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon actual historical stock price movements. The expected term of options granted is based upon historical experience and represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
 
Options granted to employees and directors:
 
The fair value of the Company's stock options granted in the years ended December 31, 2024, 2023 and 2022 was estimated using the following weighted average assumptions:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Risk free interest
    
3.85%-4.56
%
    
3.57%-4.58
%
    
1.41%-4.15
%
Dividend yields
    
0
%
    
0
%
    
0
%
Volatility
    
47.75%-49.00
%
    
52.77%-53.87
%
    
51.45%-52.95
%
Expected term (in years)
    
3.82-3.83
      
3.85-3.92
      
3.92-4.00
  
 
A summary of employees’ and directors’ option balances under the 2008 Plan as of December 31, 2024 and changes during the year then ended are as follows:
 
   
Number of options
    
Weighted-average
exercise price
    
Weighted- average
remaining
contractual term
(in years)
    
Aggregate intrinsic
value
(in thousands)
  
                         
Outstanding as of January 1, 2024
    
5,679,775
    
$
6.9
      
4.2
    
$
817
  
                                 
Granted
    
355,000
    
$
5.6
                  
Exercised
    
(76,875
)
  
$
6.4
                  
Forfeited and cancelled
    
(667,275
)
  
$
9.1
                  
                                 
Outstanding as of December 31, 2024
    
5,290,625
    
$
6.6
      
3.6
    
$
1,060
  
                                 
Exercisable as of December 31, 2024
    
2,203,333
    
$
6.9
      
2.8
    
$
268
  
 
The weighted-average grant-date fair value of options granted during the years ended December 31, 2024, 2023 and 2022 were $2.14, $2.50 and $3.08, respectively.
 
The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on that date. These amounts changed based on the fair market value of the Company's stock. Total intrinsic value of options exercised for the years ended December 31, 2024, 2023 and 2022 was $6, $104 and $565, respectively.
 
Additional stock-based compensation data:
 
As of December 31, 2024, there was $5,283 of unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the 2008 Plan. The cost is expected to be recognized over a weighted-average period of 2.32 years.
 
  c.
As part of DataPath Inc. (“DPI”) acquisition (see Note 17), the Company issued ordinary shares and may issue additional ordinary shares in the future if certain criteria are met. For additional details, see Note 17.
 
  d.
During the years ended December 31, 2024, 2023 and 2022, the stock-based compensation expenses, including with respect to the Service Based Earn-Out and the Additional Earn-Out Consideration as defined in Note 17, were recognized in the consolidated statement of income (loss) in the following line items:
 
   
Year ended December 31,
  
   
2024
    
2023
    
2022
  
                   
Cost of revenues of products
  
$
214
    
$
185
    
$
147
  
Cost of revenues of services
    
304
      
222
      
146
  
Research and development expenses, net
    
674
      
654
      
427
  
Selling and marketing expenses
    
611
      
417
      
456
  
General and administrative expenses
    
4,923
      
1,945
      
1,044
  
                         
   
$
6,726
    
$
3,423
    
$
2,220
  
 
  e.
Dividends:
     
  1.
In the event that cash dividends are declared by the Company, such dividends will be declared and paid in Israeli currency. Under current Israeli regulations, any cash dividend paid in Israeli currency in respect of ordinary shares purchased by non-residents of Israel with non-Israeli currency, may be freely repatriated in such non-Israeli currency, at the exchange rate prevailing at the time of repatriation.
 
  2.
The Company has not adopted a policy regarding the distribution of dividends.
 
  3.
Pursuant to the terms of a bank agreement, the Company is restricted from paying cash dividends to its shareholders without initial approval from the bank.